{"id":"https://openalex.org/W4389259016","doi":"https://doi.org/10.1182/blood-2023-182155","title":"Predictive Biomarkers of Response to Luspatercept in Patients with Myelofibrosis- (MF) Associated Anemia: Biomarker Analysis from the ACE-536-MF-001 Study","display_name":"Predictive Biomarkers of Response to Luspatercept in Patients with Myelofibrosis- (MF) Associated Anemia: Biomarker Analysis from the ACE-536-MF-001 Study","publication_year":2023,"publication_date":"2023-11-02","ids":{"openalex":"https://openalex.org/W4389259016","doi":"https://doi.org/10.1182/blood-2023-182155"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2023-182155","doi":"https://doi.org/10.1182/blood-2023-182155","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2023-182155","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5051235437","display_name":"Danny V. Jeyaraju","orcid":"https://orcid.org/0000-0002-5562-3833","observed_orcids":["https://orcid.org/0000-0002-5562-3833"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Danny Jeyaraju","raw_affiliation_strings":["1Translational Development and Diagnostics, Bristol Myers Squibb, Summit, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Translational Development and Diagnostics, Bristol Myers Squibb, Summit, NJ","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014419779","display_name":"Sheida Hayati","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sheida Hayati","raw_affiliation_strings":["2Informatics and Predictive Sciences, Bristol Myers Squibb, Princeton, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Informatics and Predictive Sciences, Bristol Myers Squibb, Princeton, NJ","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055316308","display_name":"Niloufar Marsousi","orcid":"https://orcid.org/0000-0001-5727-4035","observed_orcids":["https://orcid.org/0000-0001-5727-4035"]},"institutions":[{"id":"https://openalex.org/I47396830","display_name":"Bristol-Myers Squibb (Switzerland)","ror":"https://ror.org/02xqc6638","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I47396830"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Niloufar Marsousi","raw_affiliation_strings":["3Bristol Myers Squibb, Boudry, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Bristol Myers Squibb, Boudry, Switzerland","institution_ids":["https://openalex.org/I47396830"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023728016","display_name":"Aaron Thomas Gerds","orcid":"https://orcid.org/0000-0002-3422-1309","observed_orcids":["https://orcid.org/0000-0002-3422-1309"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aaron T. Gerds","raw_affiliation_strings":["4Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009381933","display_name":"Francesco Passamonti","orcid":"https://orcid.org/0000-0001-8068-5289","observed_orcids":["https://orcid.org/0000-0001-8068-5289"]},"institutions":[{"id":"https://openalex.org/I189158943","display_name":"University of Milan","ror":"https://ror.org/00wjc7c48","country_code":"IT","type":"education","lineage":["https://openalex.org/I189158943"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Francesco Passamonti","raw_affiliation_strings":["5University of Milano Statale, Milano, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5University of Milano Statale, Milano, Italy","institution_ids":["https://openalex.org/I189158943"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Fabian Sanabria","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I47396830","display_name":"Bristol-Myers Squibb (Switzerland)","ror":"https://ror.org/02xqc6638","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I47396830"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Fabian Sanabria","raw_affiliation_strings":["3Bristol Myers Squibb, Boudry, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Bristol Myers Squibb, Boudry, Switzerland","institution_ids":["https://openalex.org/I47396830"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048074124","display_name":"Sadanand Vodala","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sadanand Vodala","raw_affiliation_strings":["6Hematology, Translational Medicine and Disease Team, Bristol Myers Squibb, Summit, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Hematology, Translational Medicine and Disease Team, Bristol Myers Squibb, Summit, NJ","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043395223","display_name":"Anita Krithivas Gandhi","orcid":"https://orcid.org/0000-0001-5512-1625","observed_orcids":["https://orcid.org/0000-0001-5512-1625"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anita K. Gandhi","raw_affiliation_strings":["1Translational Development and Diagnostics, Bristol Myers Squibb, Summit, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Translational Development and Diagnostics, Bristol Myers Squibb, Summit, NJ","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5032043830","display_name":"Rajasekhar N.V.S. Suragani","orcid":"https://orcid.org/0000-0003-2754-1782","observed_orcids":["https://orcid.org/0000-0003-2754-1782"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rajasekhar N.V.S. Suragani","raw_affiliation_strings":["7Hematology, Translational Medicine and Disease Team, Bristol Myers Squibb, Summit, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Hematology, Translational Medicine and Disease Team, Bristol Myers Squibb, Summit, NJ","institution_ids":["https://openalex.org/I4210091812"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5000,"currency":"USD","value_usd":5000},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"142","issue":"Supplement 1","first_page":"6330","last_page":"6330"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10554","display_name":"Hemoglobinopathies and Related Disorders","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/luspatercept","display_name":"luspatercept","score":0.921999990940094},{"id":"https://openalex.org/keywords/myelofibrosis","display_name":"myelofibrosis","score":0.9490000009536743},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.9700000286102295},{"id":"https://openalex.org/keywords/tgf-beta-signaling","display_name":"TGF-beta signaling","score":0.6869999766349792},{"id":"https://openalex.org/keywords/erythropoiesis","display_name":"erythropoiesis","score":0.8759999871253967},{"id":"https://openalex.org/keywords/ruxolitinib","display_name":"ruxolitinib","score":0.8059999942779541},{"id":"https://openalex.org/keywords/transfusion-dependence","display_name":"transfusion dependence","score":0.8339999914169312},{"id":"https://openalex.org/keywords/jak2-mutation","display_name":"JAK2 mutation","score":0.47699999809265137},{"id":"https://openalex.org/keywords/jak2-v617f-mutation","display_name":"JAK2 V617F mutation","score":0.6579999923706055},{"id":"https://openalex.org/keywords/jak2-exon-12-mutation","display_name":"JAK2 exon 12 mutation","score":0.6100000143051147},{"id":"https://openalex.org/keywords/tet2-mutation","display_name":"TET2 mutation","score":0.3630000054836273},{"id":"https://openalex.org/keywords/dnmt3a-mutation","display_name":"DNMT3A mutation","score":0.6150000095367432},{"id":"https://openalex.org/keywords/asxl1-mutation","display_name":"ASXL1 mutation","score":0.6299999952316284},{"id":"https://openalex.org/keywords/cytokine-profile","display_name":"cytokine profile","score":0.3059999942779541}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.847964882850647},{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.8104739785194397},{"id":"https://openalex.org/C2776112149","wikidata":"https://www.wikidata.org/wiki/Q7383611","display_name":"Ruxolitinib","level":4,"score":0.807809591293335},{"id":"https://openalex.org/C2778248108","wikidata":"https://www.wikidata.org/wiki/Q5445","display_name":"Anemia","level":2,"score":0.6530640125274658},{"id":"https://openalex.org/C2781107747","wikidata":"https://www.wikidata.org/wiki/Q1898104","display_name":"Myeloproliferative neoplasm","level":4,"score":0.6208375692367554},{"id":"https://openalex.org/C2779703530","wikidata":"https://www.wikidata.org/wiki/Q837174","display_name":"Erythropoiesis","level":3,"score":0.6018353700637817},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5774360299110413},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.4951614439487457},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.47306501865386963},{"id":"https://openalex.org/C2780240888","wikidata":"https://www.wikidata.org/wiki/Q6052586","display_name":"International Prognostic Scoring System","level":4,"score":0.43509453535079956},{"id":"https://openalex.org/C2780817109","wikidata":"https://www.wikidata.org/wiki/Q954625","display_name":"Myelodysplastic syndromes","level":3,"score":0.4219111502170563},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.4203298091888428},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3578113913536072},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.3477116823196411},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2023-182155","doi":"https://doi.org/10.1182/blood-2023-182155","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2023-182155","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4379339513","https://openalex.org/W4389233748","https://openalex.org/W2991379201","https://openalex.org/W4417007197","https://openalex.org/W4386332317","https://openalex.org/W4417004485","https://openalex.org/W3097057554","https://openalex.org/W4399203533","https://openalex.org/W4389259064","https://openalex.org/W4385665567"],"abstract_inverted_index":{"Introduction:":[0],"MF":[1],"is":[2,66,86],"a":[3,67,187,302,424,534,654],"clonal":[4],"myeloproliferative":[5],"neoplasm":[6],"that":[7,75,400],"results":[8],"in":[9,28,88,112,269,294,317,340,369,442,509,515,577,607,640,653],"fibrosis":[10],"of":[11,31,56,110,115,124,190,197,223,281,328,348,461,472,478,497,602,634,657],"the":[12,77,106,113,377,387,404,458,612,626],"bone":[13],"marrow":[14],"and":[15,33,54,81,94,108,121,133,152,159,169,184,279,288,337,371,408,456,482,486,504,513,521,544,565,568,571,591,636],"impaired":[16],"hematopoiesis.":[17],"Among":[18],"other":[19],"clinical":[20,358,446],"manifestations,":[21],"ineffective":[22],"erythropoiesis":[23],"leads":[24],"to":[25,130,180,207,314,346,428,469,604],"anemia":[26,47,217,370,429,525,586],"resulting":[27],"poor":[29],"quality":[30],"life":[32],"reduced":[34],"overall":[35],"survival":[36],"(Passamonti":[37],"et":[38,59,381],"al.,":[39,60],"Blood":[40],"2010).":[41],"Current":[42],"treatment":[43,114,153,606],"options":[44],"for":[45,201,231,238,243,257,262,274,285,326,355],"MF-associated":[46],"with":[48,91,137,154,204,357,410,414,448,524,553,562,609],"most":[49,401],"agents":[50],"lack":[51],"optimal":[52],"efficacy":[53,109],"durability":[55],"response":[57,218,430,535,554,603,628],"(Cervantes":[58],"Expert":[61],"Rev":[62],"Hematol.,":[63],"2016).":[64],"Luspatercept":[65,85],"transforming":[68],"growth":[69],"factor-\u03b2":[70],"(TBF-\u03b2)":[71],"family":[72],"ligand":[73],"trap":[74],"inhibits":[76],"TGF-\u03b2-Smad":[78],"signaling":[79],"axis":[80],"promotes":[82],"late-stage":[83],"erythropoiesis.":[84],"approved":[87],"low-risk":[89],"MDS":[90],"ring":[92],"sideroblasts":[93],"\u03b2-thalassemia":[95],"requiring":[96],"red":[97],"blood":[98,298],"cell":[99],"(RBC)":[100],"transfusion.":[101],"The":[102,642],"ACE-536-MF-001":[103,125],"study":[104],"investigates":[105],"safety":[107],"luspatercept":[111,198,449,605],"MF-related":[116],"anemia.":[117],"Here,":[118],"through":[119],"mutational":[120,132,397],"cytokine":[122,134],"analysis":[123,291,398,500,598],"biomarker":[126,388],"samples,":[127],"we":[128],"sought":[129],"identify":[131],"profiles":[135],"associated":[136,523,552,561],"response.":[138,359,498,526],"Methods:":[139],"Eligible":[140],"patients":[141,173,193,373,402,409,441,608,658],"were":[142,161,171,353,490,546],"divided":[143],"into":[144],"4":[145,362,395],"cohorts":[146,167,232,244,263,286,363,455],"based":[147],"on":[148],"transfusion":[149,163,236,528],"dependence":[150],"(TD)":[151],"ruxolitinib":[155],"(RUX).":[156],"Cohorts":[157,182],"1":[158,335,345,503],"3A":[160,183],"non":[162],"dependent":[164],"(NTD)":[165],"while":[166],"2":[168,287],"3B":[170,185,444,620],"TD":[172,372],"receiving":[174,374,622],"4-12":[175],"RBC":[176,235,270,282],"units/84":[177],"days":[178],"up":[179,206],"C1D1.":[181],"received":[186,194],"stable":[188],"dose":[189],"RUX.":[191],"All":[192,361],"1.0":[195],"mg/kg":[196,200,209],"(1.33":[199],"cohort":[202,389,443,619,656],"3B)":[203],"titration":[205],"1.75":[208],"once":[210],"every":[211],"21":[212],"days.":[213],"Primary":[214],"endpoint":[215,247],"was":[216,248,292,312,324,463,531,560],"(defined":[219],"as":[220,533],"an":[221],"increase":[222,251,559],"\u2265":[224,239,252,258,266,275],"1.5":[225,253],"g/dL":[226,254],"hemoglobin":[227],"(Hgb)":[228],"from":[229,255,272,296,343],"baseline":[230,256,273,465,639],"1/3A":[233],"or":[234,265,412,421],"free":[237],"12":[240,259,276],"consecutive":[241,260,277],"weeks":[242,261,278],"2/3B).":[245],"Secondary":[246],"mean":[249],"Hgb":[250,558,583],"1/3A,":[264],"50%":[267],"decrease":[268,514],"transfusions":[271],"duration":[280],"transfusion-free":[283],"period":[284],"3B.":[289],"Mutational":[290],"performed":[293],"DNA":[295],"peripheral":[297],"mononuclear":[299],"cells":[300],"using":[301],"panel":[303,311,323],"targeting":[304],"74":[305],"genes.":[306],"Rules-Based":[307],"Medicine's":[308],"Human":[309],"Inflammation":[310],"used":[313,325,532],"measure":[315],"changes":[316],"54":[318],"serum":[319],"cytokines.":[320,475],"Nexelis":[321],"custom":[322],"detection":[327],"GDF8,":[329],"GDF15,":[330],"erythroferrone,":[331],"soluble":[332,341],"transferrin":[333],"receptor":[334],"(sTfR1)":[336],"hepcidin.":[338],"Changes":[339],"factors":[342],"cycle":[344,502],"end":[347],"week":[349,505],"24":[350,506],"(day":[351],"169)":[352],"examined":[354],"correlation":[356],"Results:":[360],"(N":[364],"=":[365,391],"95)":[366],"displayed":[367],"improvement":[368],"RUX":[375],"had":[376,423,625,631],"greatest":[378],"benefit":[379,447],"(Gerds":[380],"al.":[382],"EHA":[383],"2023":[384],"S167).":[385],"In":[386,437,556],"(n":[390],"63":[392],"across":[393,617],"all":[394],"cohorts),":[396],"revealed":[399,507],"carried":[403],"JAK2":[405,439],"V617F":[406,440],"mutation,":[407],"SF3B1":[411,413],"co-occurring":[415],"DTA":[416],"mutations":[417],"(":[418,492,548],"DNMT3A,":[419],"TET2":[420],"ASXL1)":[422],"favorable":[425],"prognosis":[426],"related":[427],"(p=":[431],"0.0260,":[432],"0.0495;":[433],"OR=":[434],"3.54,":[435],"3.86).":[436],"addition,":[438,557],"showed":[445],"(OR=":[450],"6.75,":[451],"p=":[452],"0.0445).":[453],"Across":[454],"endpoints,":[457],"general":[459],"trend":[460],"responders":[462],"low":[464],"(2-3-fold":[466],"lower":[467],"relative":[468],"nonresponders)":[470],"levels":[471,477,567,633],"key":[473],"inflammatory":[474],"Low":[476],"IL-10":[479],"(TD":[480],"patients)":[481,489],"VCAM-1,":[483],"TNFR2,":[484],"CRP":[485],"IL-18":[487],"(NTD":[488],"significant":[491],"P":[493,549],"<":[494,550],"0.01)":[495],"predictors":[496,601],"Paired":[499],"between":[501],"increases":[508],"alpha-2-macroglobulin,":[510],"haptoglobin,":[511],"TIMP1,":[512],"C3,":[516],"vitamin":[517],"D-binding":[518,588],"protein,":[519,589],"hepcidin":[520],"sTfR1":[522],"When":[527],"burden":[529],"reduction":[530],"criterion,":[536],"ferritin,":[537],"hepcidin,":[538,581],"thrombopoietin,":[539],"von":[540],"Willebrand":[541],"Factor,":[542],"sTfR1,":[543],"beta-2-microglobulin":[545],"significantly":[547],"0.05)":[551],"(Figure).":[555],"increased":[563],"TGF-\u03b21":[564],"VEGF":[566],"decreased":[569],"GDF-15":[570],"ERFE.":[572],"These":[573],"cytokines":[574],"are":[575],"implicated":[576],"iron":[578],"metabolism":[579],"(ferritin,":[580],"alpha-2-macroglobulin),":[582],"catabolism":[584],"(haptoglobin),":[585],"(vitamin":[587],"C3),":[590],"luspatercept-target":[592],"engagement":[593],"(hepcidin,":[594],"sTfR1).":[595],"Conclusions:":[596],"Our":[597],"identifies":[599],"unique":[600],"MF.":[610],"While":[611],"data":[613],"describe":[614],"our":[615],"findings":[616],"cohorts,":[618],"(TD,":[621],"RUX),":[623],"which":[624],"highest":[627],"rate,":[629],"also":[630],"higher":[632],"RANTES":[635],"TPO":[637],"at":[638],"responders.":[641],"ongoing":[643],"phase":[644],"3":[645],"study,":[646],"INDEPENDENCE":[647],"(NCT04717414),":[648],"would":[649],"validate":[650],"these":[651],"observations":[652],"larger":[655]},"counts_by_year":[{"year":2024,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-12-02T00:00:00"}